Idorsia Ltd
🇨🇭Switzerland
Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04286750
- Locations
- 🇵🇹
BlueClinical Phase 1 Hospital de Prelado, Porto, Portugal
To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: Matching placeboOther: Moxifloxacin control to establish assay sensitivity
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04281342
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: Combined oral contraceptives (COC)Drug: Matching PlaceboOther: Charcoal, activated
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT04255277
- Locations
- 🇫🇷
Site 1, Rennes, France
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT04252495
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇵🇱Biokinetica S.A., Jozefow, Poland
A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04250506
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ACT-1014-6470 (MAD)Drug: ACT-1014-6470 (SAD)Drug: Placebo (MAD)Drug: Placebo (SAD)Drug: 14C-ACT-1014-6470 microtracerDrug: 14C-ACT-1014-6470 microtracer placebo
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT04183686
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
Phase 3
Withdrawn
- Conditions
- HypertensionRenal Insufficiency, Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Registration Number
- NCT04162366
A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04123288
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04052360
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04024332
- Locations
- 🇩🇪
APEX GmbH, München, Germany